Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    19226361 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Dietary Supplement: ascorbic acid;   Drug: bortezomib;   Drug: melphalan

Indicates status has not been verified in more than two years